Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

3SBio Inc.

www.3sbio.com

Latest From 3SBio Inc.

Venture Funding Deals: Tenaya's $92m, Nuvation's $275m Lead October Rounds

Former Medivation CEO David Hung launched stealthy oncology start-up Nuvation with $275m in series A venture capital, while Tenaya's series B brought in $92m for small molecules as well as cell and gene therapies to treat cardiovascular diseases.

Deals Financing

Finance Watch: BIO Says Proposed Foreign Investment Regulations Will Lower Investment In US Biotech

Private Company Edition: BIO comments suggest definitions of personal data expand the scope of foreign investments in biotech companies that must be reviewed by the Committee on Foreign Investment in the United States (CFIUS). Also, NeuroRx’s $95m deal leads recent private financings.

Financing Regulation

Chinese Biosimilar Boom Is Heralded By First Approval

Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.

China Biosimilars

Biosimilar Boom in China Heralded By First Approval

Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.

China Biosimilars
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Generic Drugs
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Inflammation
  • Renal System
  • Alias(es)
  • Shenyang Sunshine Pharmaceutical Co. Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • 3SBio Inc.
  • Senior Management
  • Jing Lou, PhD, Chmn., Pres. & CEO
    Bo Tan, EVP, CFO
    Zhenping Zhu, PhD, Pres., R&D & CSO
  • Contact Info
  • 3SBio Inc.
    Phone: (86) 24 2581 1820
    No. 3 A1, Rd. 10
    Shenyang, 110027
    China
UsernamePublicRestriction

Register